Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5-Δ24-RGD-BiTE
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
Ad5-Δ24-RGD-BiTE is an engineered oncolytic adenovirus (OV) designed as a gene therapy platform to express a bispecific T-cell engager (BiTE). The viral backbone, based on Adenovirus type 5, features two key modifications for oncology: a 24-base pair deletion (Δ24) in the E1A region that restricts replication to cells with a disrupted Rb pathway (common in cancer cells), and an Arg-Gly-Asp (RGD) motif insertion in the fiber knob to enhance viral entry via integrins. This specific construct encodes a BiTE that simultaneously targets the T-cell marker CD3 and the tumor-associated antigen IL-13Rα2, which is highly expressed in glioblastoma. By combining direct viral-mediated oncolysis with the localized secretion of BiTEs, the therapy aims to overcome the immunosuppressive tumor microenvironment and recruit T cells to the tumor site, often used in synergy with CAR-T cell therapies.
- Other names
- Ad5-Delta24-RGD-BiTEAd-5-Delta24-RGD-BiTEAd 5-Delta24-RGD-BiTEOncolytic Adenovirus encoding BiTE
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)αVβ5 (Integrin αVβ5)CD3 (T-cell surface glycoprotein CD3)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on Ad5-Δ24-RGD-BiTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5-Δ24-RGD-BiTE.